Diamyd Medical acquires property with manufacturing facility in Umeå, Sweden

Diamyd Medical today announes the acquisition of the property in Umeå where prodution of the recombinant protein GAD65, the active component in the therapeutic diabetes vaccine Diamyd[®] is being established. The property is acquired for a purchase price of SEK 24.5 million and comprises approximately 20 000 square feet including the 10 000 square feet Diamyd Medical rents today, as well as 90 000 square feet of land area.“The manufacturing facility is a crucial investment for the future and the acquisition gives us further opportunities to scale up and expand our manufacturing activities”,